As expected, the loss of CCR2 led to a profound reduction of circulating CD11b+ myeloid cells (>80% reduction; Supplemental Figure 5B), which resulted in a concomitant decrease in the PDA stroma (Supplemental Figure 5C). The gene discussed is CCR2; the disease is Patent ductus arteriosus.